Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Nilanjana Maulik

Nilanjana Maulik

University of Connecticut Health Center, USA

Title: Regeneration of infarcted myocardium by genetically modified stem cells

Biography

Biography: Nilanjana Maulik

Abstract

Implantation of mesenchymal stem cells (MSC) is becoming an exciting new method for promoting repair of infarcted myocardium. In this study, we use an adenoviral vector encoding Thioredoxin-1 (Ad.Trx1) to genetically modify MSCs prior to implantation. Trx-1 has been established as a redox regulator of growth and transcription-factors as well as a cofactor. It has also been shown to be a potential antioxidant. We wanted to study whether Trx-1 engineered MSCs are capable of improving cardiac function and angiogenesis in a rat myocardial infarction (MI) model. In order to do so, rat MSCs were cultured and divided into three groups: MSC, MSC-LacZ and MSC-Trx1. The cells were assayed for survivability, proliferation and differentiation potential. Additionally, rats were randomized into control Sham (CS), control MI (CMI), MSC-LacZMI (MLZMI) and MSC-Trx1MI (MTRXMI) groups (n=20 per group). MI was induced by permanent occlusion of the LAD immediately after which MSCs preconditioned with either Ad.LacZ or Ad.Trx1 were administered at 4 peri-infarct areas. We observed increased proliferation of MSC-Trx1 cells in vitro that maintained pleuripotency to divide into cardiomyocytes, smooth muscle and endothelial cells. In treated rats, capillary density increased in the MTRXMI group when compared to the both the CMI and MLZMI groups. Western blot analysis showed increased expression of VEGF, HO-1 and CXCR4 and decreased expression of TXNIP in the MTRXMI group. Increased intercellular connections, measured by Cx-43 expression, were seen in the treatment group. Echocardiography showed improved ejection fractions and fractional shortening in Trx-1 treated mice when compared to LacZ and control mice. Additionally, picro-sirus red staining showed Trx-1 treated mice had decreased levels of fibrosis in the myocardium. Trx-1 pretreated MSCs provide protection against myocardial injury via induction of VEGF expression, promotion of neovascularization, reducing fibrosis and increasing functional recovery. Ischemic damage cause by decreased blood flow may be reversed in various cardiovascular diseases by treatment with MSCs preconditioned with Trx-1. The long term clinical management of illnesses, such as MI or peripheral vascular disease, may benefit from the angiogenic properties of Trx-1.